## HOW BIOMARKERS CONTRIBUTE TO SUSTAINABLE HEALTHCARE

## THE CHALLENGE

An increase in cancer incidence by 31% between 1995 and 2012, spurred by a growing and ageing population. This trend is likely to continue in the future, leading to budget pressure on healthcare systems.<sup>3</sup>

### THE GOOD NEWS

In the same period, fewer people died of cancer thanks to advances in screening, diagnosis, and treatment.<sup>3</sup>



**Tumour Incidence** 2.609 to 3.414 million<sup>3</sup>

**Cancer Mortality** 1.192 to 1.319 million<sup>3</sup>

#### What are biomarkers?4

They are indicators that provide information about normal biological processes, disease processes, or responses to a therapeutic intervention.

Examples of biomarkers include everything from pulse and blood pressure through basic chemistries to more complex laboratory tests of blood and other tissues:<sup>5</sup>



#### BIOMARKERS HELP...

- Improve health outcomes: The right patient gets the right treatment at the right time<sup>1</sup>
- Make research and development of new medicines more efficient: Biomarkers help to increase the success rates in clinical trials<sup>6</sup>
- Create more sustainable health systems: Patients avoid receiving medicines that do not provide additional benefit<sup>1</sup>

# THE RIGHT PATIENT RECEIVES THE RIGHT MEDICINE



#### **References:**

- Ref. 1: Chantelot et al. Realising the potential of personalized medicines in Europe. September 2014. EuropaBio White paper. Ref. 2: Godman et al. Personalizing health care: feasibility and future
- Ber 2: Gournan et al. Personalizing negative care, reasoning and to implications. BMC Medicine 2013; 11:179. doi: 10.1186/1741-7015-11-179.
   Ref. 3: Jönsson, B., Hofmarcher, T., Lindaren, P., Wilking, N.
- Ref. 3: Jönsson, B., Hofmarcher, T., Lindgren, P., Wilking, N. Comparator report on patient access to cancer medicines in Europe revisited. IHE Report 2016:9, IHE: Lund.
- Ref. 4: Bücheler M. et al. Personalised Medicine, in Europe- Enhancing Patient Access to Pharmaceutical Drug-Diagnostic Companion Products, Patient Access Study Nov. 2014. EPEMED White Paper, Charite, Berlin.
- Ref. 5: Strimbu et al. What are Biomarkers? Curr Opin HIV AIDS 2010;5:463-466.
  Ref. 6: Jörgensen JT. The importance of predictive biomarkers in oncology drug develpment. Expert Review of Molecular Diagnostics 2016, 16:8, 807-809, DOI: 10.1080/14737159.2016.1199962.

